MedTrace Logo

Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands

NCT01273597 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2013-01-18

Study results available
· View outcomes & findings →

Summary

This observational study will evaluate the clinical benefit of Zemplar (paricalcitol injection) in daily routine practice in end-stage renal disease patients with severe over-reactivity of parathyroid glands. Participants will be followed for 6 months. Data will be collected from participants initiated on Zemplar therapy according to standard of care. The time to achieving the maintenance dose of Zemplar (paricalcitol injection), the proportion of participants achieving target parathyroid hormone levels, and prevalence of elevated serum calcium and phosphate levels will be evaluated.

Conditions

  • Kidney Failure, Chronic

Sponsors & Collaborators

  • Planimeter Ltd

    collaborator UNKNOWN

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Tamas Schnaider · AbbVie (prior sponsor, Abbott)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01273597 on ClinicalTrials.gov